宫颈癌组织表皮生长因子受体对TKI敏感性相关的基因突变研究

摘要

目的 研究宫颈癌组织表皮生长因子受体(epidermal growth factor receptor,EGFR)基因中是否存在与EGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)药物敏感性相关的18、19及21外显子突变,为本地区宫颈癌的靶向治疗提供依据.方法 收集70例宫颈癌患者的新鲜癌组织标本,提取DNA,以特异性引物PCR扩增EGFR基因外显子18、19及21,进行DNA测序并分析序列相似性.结果 70例宫颈癌组织提取质量良好的DNA中,均未检测到EGFR基因18、19及21外显子突变.结论 宫颈癌组织EGFR基因外显子18、19及21突变罕见.%Objective To detect whether in epidermal growth factor receptor (EGFR) there exists mutation of exons 18, 19 and 21 associated with tyrosine kinase inhibitor (TKI) medication-sensitivity in cervical cancer patients for the purpose of providing evidence for targeting treatment of cervical cancer in the region. Methods Fresh tissue specimens were collected from 70 patients with cervical cancer and DNA was extracted from these specimens. Exons 18, 19 and 21 of EGFR were amplified with designed specific primers and DNA templates extracted from cervical cancer tissues. Then, the PCR products were sequenced on DNA sequencer, and the sequences were BLAST analyzed. Results No mutations were detected in exons 18, 19 or 21 of EGFR in the 70 human cervical cancer samples analyzed. Conclusion Mutations in exons 18, 19 and 21 of EGFR are very rare in cervical cancer.